A phase 2 a, randomized open label study to evaluate the efficacy, safety tolerability, pharmocokinetics and pharmacodynamics of ISIS 702843 Administered subcutaneously to patients with non-transfusion depenmdent B- thalassemia intermedia
Karakaş Z. (Executive), Tanyıldız H. G.
Other International Funding Programs, 2021 - 2023
-
Project Type:
Other International Funding Programs
-
Begin Date:
April 2021
-
End Date:
April 2023